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The Dynamics of Insight in the
Prodrome of Schizophrenia
By Robert G. Bota, MD, J. Stuart Munro MD,
Walter F. Ricci, MD, and Daniela A. Bota, MD, PhD
ABSTRACT
Introduction: Schizophrenia is charac-
terized by diminished insight, which fluc-
tuates with disease progression. Insight
deterioration in the prodrome of schizo-
phrenia is poorly understood. Despite
pharmacologic treatment, including
early interventions, there is a high risk of
relapse and need of acute care in schizo-
phrenia patients.
Objective:To study if insight deteriora-
tion occurs during the prodrome and if
insight preservation early in the illness
might predict a better prognosis.
Methods: Data was collected retro-
spectively from the records of 24 patients
initially diagnosed with schizophrenia
during a 2-year period. Patients' progress
was then tracked over a 3-year period.
Insight was determined by a physician's
subjective evaluation, patient interest and
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participation in treatment planning, and patient
accuracy in reporting behaviors and symptoms
when compared with reports from collaterals.
Results:Ten patients were determined to have
insight regarding the developing illness at differ-
ent presentations at the hospital. Insight preser-
vation correlated with less need for emergency
visits and fewer hospitalization days (P<.005). It
was also associated with more depressive and
anxious mood (P<.000). Patients and family
members described early, ego-dystonic percep-
tual disturbances followed by diminished insight.
Awareness into the illness, symptoms, and attri-
bution of symptoms to the illness fluctuated at
different presentations in the insight group. In the
other group, insight was nil at each presentation
after the psychotic debut.
Conclusion: Most patients maintain insight
during the perceptual disturbance phase. Insight
diminishes as the early delusional phase sets in.
Higher levels of preserved insight seem to cor-
relate with less need for acute treatment. Further
research in this area is warranted for determin-
ing if early insight oriented interventions in the
prodromal phase can improve the prognosis of
schizophrenia.
CNSSpectr. 2006;11 (5)355-362
INTRODUCTION
Of the factors influencing schizophrenia's
disease course, family environment, substance
abuse, and duration of untreated psychosis,18
are the most important modifiable predictors of
outcome. Early detection can reduce the dura-
tion of untreated psychosis46811 and predict more
favorable outcomes12 although some studies1315
fail to support this hypothesis.
For research and clinical purposes, insight is
defined along five dimensions: one's awareness
of having a mental disorder, the social conse-
quences of the illness, the need for treatment,
the symptoms in particular, and the relatedness
of symptoms to the disorder.16 However, reflec-
tive capacity in one domain does not predict
reflective capacity in other domains.17The Scale
to Assess Unawareness of Mental Disorder,18
the gold standard in the field, addresses such
issues. Lack of awareness in various aspects of
the illness specifically correlates with degree of
impairment in cognitive, affective, and psychotic
symptoms.19 Sevy and colleagues20 proposed
that lack of insight into the symptoms corre-
lates with severity of illness, poor insight into
consequence of illness correlates with positive
symptoms, and poor insight into the need for
treatment correlates with poor cognition.
Insight preservation in these domains is impor-
tant because it predicts quicker resolution of
symptoms with less hospitalization in the period
of time leading to relapse.21 Schizophrenia is char-
acterized by diminished insight, which fluctuates
with illness progression. Overall, patients have
more insight regarding the negative rather than
the positive symptoms of the illness.22 Insight
impairment is associated with cognitive and
executive declines in multiple domains and is
common in early schizophrenia.2324 Also, schizo-
phrenia patients with poor insight into the illness
show decreased volume of the right dorsolateral
prefrontal cortex on magnetic resonance imaging
(MRI) when compared with patients with good
insight.25 Good insight correlates with symptoms
of depression, paranoia,26 and anxiety.27 In one
study,28 no difference between males and females
in insight scores was reported.
The period of time leading to the first episode of
psychosis in schizophrenia is characterized by non-
specific symptoms described as schizotaxia,29 the
pre-prodromal period, and the prodrome.30 Insight
deterioration in the pre-schizophrenia period is
poorly understood. It can be hypothesized that
insight declines during the late prodromal phase
with the debut of incipient delusional systems
and that is influenced by growing affective distur-
bances. While the correlations described above
refer to level of insight in persons with schizophre-
nia,1631 there is currently no data regarding insight
in the prodromal period (Figure 1).
Various interventions have been shown to
improve insight in patients with schizophrenia.
Aguglia and colleagues32 reported improvement
in insight in patients diagnosed with schizophre-
nia who were switched from conventional to
atypical antipsychotic medication. Nieznanski
and colleagues33 reported that patients that had
12 sessions of performing cognitive tasks or
receiving psychoeducation had increases in the
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insight scores. Furthermore, Rusch and Corrigan34
proposed that motivational therapy with specific
modification for persons with schizophrenia can
improve insight and compliance with treatment,
allowing the patients to take a more active role
in their treatment. Siver advocates the use of
insight-enhancing psychotherapy for patients
with schizophrenia as a tool for improvement in
medication compliance.35
METHODS
For this study, we selected all the records
for patients with first diagnosis of schizophre-
nia at a publicly funded state hospital over
a period of 2 years.Their progress was then
tracked over a 3-year period.
Patients with mental retardation, pervasive
developmental disorders, documented moder-
ate to severe central nervous system damage,
and patients with degenerative neurological
FIGURE 1 .
Theoretical Model of Insight'
* The selected information from sensory receptors is transformed in primitive
awareness (stepping on a branch in the dark and reacting as if it would be
an immediate threat). Some of these sensations are processed through
working memory and referred to stored reference information through
the association areas becoming perceptions. The perceptions are closely
correlated with awareness of the symptoms. They are further processed
mostly through working memory and lead to knowledge (a posteriori). This
can be understood as fostering the understanding of the relation between
symptoms as contributors to illness. Through repetition, ideas are incorpo-
rated into meanings and beliefs. This is the basis of cognitively higher levels
of insight, such as awareness into complex relations between the social
consequences, need for treatment and illness. Some beliefs are not based
on reality (close systems—a priori thinking) such as bizarre delusions.
Meehl36 describes schizotaxia as "a conjectured neural integrative defect...
penetrant for a parametric aberration in synaptic signal aberration (hypokri-
sia) (that) gives rise under ordinary social learning regiments to schizotipy, a
personality showing ambivalence, aversive drift, dereism, autism, and cog-
nitive slipage." Therefore, we can hypothesize that deficits may happen with
various degree of severity in these domains. This is suggested by the finding
that insight in one domain does not predict insight in other domains.
sx=symptoms; sc=social consequence; tx=treatment.
Bota RG, Munro JS, Ricci WF, Bota DA. CNS Spectr. Vol 11, No 5. 2006.
disease and other medical conditions that may
induce psychotic symptoms were excluded.The
study cohort was composed of 24 patients who
met Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition-Text Revision37 (DSM-IV-
77?) schizophrenia diagnosis. All were diagnosed
for the first time at our facility.
To evaluate insight at each presentation in our
emergency department (ED), the following data
was used: the physician assessment documenting
the patient's awareness of a mental disorder, chief
complaint of the patient in terms of relatedness to
identified problem (awareness of symptoms), and
patient behavior in terms of awareness of the need
for treatment. Scores were assigned to each evalu-
ation of patients as follows: 0, 1, 2 and 3 for no,
minimal, fair and good insight (Table 1) regarding
TABLE 1 .
Emergency Department Evaluation of
Awareness*
• Awareness of a mental disorder: The physician
assessment documenting the patient's awareness
that he or she has a mental illness. This can range
from no insight (complete denial of present or
past psychiatric illness), minimal and fair insight
(vague entertainment of the concept of having an
illness, and underestimating the seriosness) to
good insight.
•Awareness of symptoms (delusions, hallucina-
tions, anhedonia): Chief complaint of the patient in
terms of relatedness to the identified problem, doc-
umentation of such behaviors indicating attribution
of symptoms. Minimal and fair awareness will cor-
respond to little awareness of the symptoms' pres-
ence and no insight corresponds to no distinction
between psychotic symptoms and reality.
• Awareness of the need for treatment and effect of
medications: Patient's treatment seeking behav-
iors, knowledge of medication effect on the illness,
interest in participation in treatment review team
meetings and requesting medication for symptoms
of schizophrenia. These elements were docu-
mented by multiple examiners in specific forms.
* Directions: For awareness domains information was collected from
several sources. First, from the structured form where there is a choice
to mark poor, fair or good insight. Secondly, it was obtained from the
initial medical and psychiatric examination describing patient behavior
and reports regarding the presence of the illness, symptoms, and
relation of medications to illness progression. Thirdly, from the initial
nursing report the patient's stated reason for the visit can be contrasted
with identified problem. All ratings were completed by the first author.
In situations where the score was not clear, it was discussed with the
chair of the program for further assessment.
The data was ranked in the following fashion: Unk=not rated, 0=no
insight, 1=minimal awareness, 2=fair understanding, or3=good insight.
Bota RG, Munro JS, Ricci WF, Bota DA. CNS Spectr. Vol 11, No 5. 2006.
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the presence of a mental disorder, awareness of
the need for treatment and awareness of symp-
toms respectively (similar to the Scale to Assess
Unawareness of Mental Disorder38). Data regarding
suicidal behavior was obtained from the standard-
ized initial interview form and scores were attrib-
uted as follows: 0, 1, 2, 3 for no, suicidal ideation
without plan, suicidal ideation with plan/suicidal
gesture, and suicidal attempt. Similar scores were
attributed to the elements of mental status exami-
nation: behavior, cooperativeness with assessment
and interventions, grooming and hygiene, mood,
affect, anxiety, attention, thought process, judge-
ment, halucinations, and delusions (Table 2).These
scores from the assessments at each hospital visit
were compared with the scores from subsequent
visits. The patients with a score of >1 per visit (for
insight) on average were compared with the other
patients in term of severity and nature of symp-
toms and need for acute care.
Data collected reflected psychiatrist assessment
in terms of diagnosis, treatment history, symp-
toms, and clinical course as well as other team
members' assessments reflecting psychological
assessments, demographics, change in support
system, and laboratory work.The clinical assess-
ment tool used by psychiatrists allowed a variety
of data collection and planning for research with
the use of valid and reliable scales, including ele-
ments of the Brief Psychotic Rating Scale,39 and
TABLE 2 .
Other Measures Used
• Suicidality: Information was gathered from the patient.
The presence of a plan was documented along with
the severity of suicidal ideation ranging from no to
mild, moderate and severe.
•Depression: This was self-reported from the patient.
Severity ranged from no depression, mild (express feeling
of sadness and hopelessness only on interview-on a sepa-
rate rubric ranging from mild to severe), moderate (symp-
toms of sadness, pessimism, guilt feelings, and cannot be
easily cheered up) to severe (severe depressive symptoms
with major interference in motor and social functioning). In
a separate rubric, there were choices including depressed,
anxious, euphoric, irritable and other descriptions of mood.
• Affect: Was evaluated by observation of patient behavior
in response to the interview. The choices presented were
appropriate, inappropriate, labile, constricted, flat, and other.
•Anxiety: Referred to both the level of self-reported anxi-
ety and behavior observed suggesting anxiety. Ranges
were from absent to mild (patient expresses same worry
and over-concern, without behavioral correlate), moder-
ate (serious anxiety symptoms with behavioral implica-
tions), and severe (almost constant fear, phobias with
marked restlessness or multiple somatic manifestations).
• Attention: After level of alertness and orientation was evalu-
ated, attention was assessed by observing the patient behav-
ior for signs of distractibility, and difficulties in attending to
the examiner. Symptoms ranged from no impairment, limited
concentration to no conversation can take place as result of
marked distraction by internal stimuli. Serial sevens, the word
"world" backwards or forward and backward digit span was
performed (with the total of 12±3 considered normal).
• Delusions: Were documented as ranging from no delu-
sional content identified, mild, moderate, and severe,
where mild severity is entertain delusional themes,
limited crystallization of the beliefs, and severe delu-
sions would correspond to bizarre delusion.
• Hallucinations: Documented in structured form simi-
larly as delusions, where mild hallucinations corre-
spond to occasional hallucinations that patient can
suppress and severe hallucinations correspond to
responding to internal stimuli.
• Evaluated the patient capacity to make a rational,
socially accepted decision about a hypothetical
situation. This was tailored to patient education.
• Thought process: Graded as ranges from absent
problems to mild (thinking is circumstantial, tangen-
tial and there is limited difficulty in directing thoughts
toward a goal), moderate (patient present with fre-
quent irrelevancies, looseness of association even
when not under pressure), and severe (incoherence,
marked looseness of associations or mutism.
• Behavior: Descriptive aspect looking at withdrawal,
motor retardation, tension, motor hyperactivity, man-
nerism/posturing, and uncooperativeness. These
symptoms were graded from normal, mild, moderate
to severe. Also, general impression was described
as cooperative, guarded, uncooperative, and other.
• Grooming and hygiene: Description with checkmark
choices good, fair, poor, and other.
* The data is obtained mainly from assessment of the patient and observation of the behavior exhibited during the interview. These do not reflect level of
awareness of patient into the symptoms. They reflect physician assessment of the patient during the interview.
The data was ranked in the following fashion: Unk=not assessed, 0=no symptoms or impairment in that domain, 1=mild symptoms/impairment, 2=moderate symp-
toms/impairment, 3=severe symptoms/impairment.
Bota RG, Munro JS, Ricci WF, Bota DA. CNS Spectr. Vol 11, No 5. 2006.
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Positive and Negative Symptoms Scale for schizo-
phrenia,40 including the Positive and Negative
Symptoms Scale excited item embedded in it.
Patient report was compared with collateral
reports, documented in standardized sections of
the social worker comprehensive assessment and
psychiatrist assessments in terms of accuracy and
symptom progression. Data gathered were ana-
lyzed using Statistical Package for Social Sciences
version 13 software for standard deviation and
Mest (2-tailed, P<.05) analysis.The University of
Missouri-Kansas City Health Science Institutional
Review Board as well as the Missouri Department
of Mental Health Institutional Review Board have
approved the study annually since 2002.
RESULTS
Demographics
Average age at the initial schizophrenia diag-
nosis was 25±9.4 years. Ethnically, 58% of these
patients were Black, 24% were white, and the
remaining were Hispanic and Asian.These patients
had achieved an average 11.1 years of education
and 29% (seven patients) were employed at the
time of initial schizophrenia diagnosis. Ninety-two
percent were never married, 58% (n=14) lived with
their families, and 33% (eight patients) were home-
less. Only 29% (seven patients) had medical insur-
ance, out of which three had Medicaid.
This patient population was divided in two sub-
groups: patients with and patients without aware-
ness in the illness.The group with better insight
did have a statistically higher level of education
(11.9±1.7 versus 10.6±2 years of education; P<.005,
df=§, t=21) and were more often employed (six of
10 versus one of 14; P=.OO5, df=§, f=3.3).
Insight
Insight Influences on Duration of
Hospitalization
Ten patients were determined to have insight
regarding the developing illness.Their insight score
fluctuated at subsequent visits and was 1.75±0.42
for 10 patients with preserved insight, (^min i -
mal, 2=fair awareness of mental disorder) and was
0.25±0.42 for the other 14 patients (P<.0009, df=9,
f=13). Insight preservation correlated with less
need for ED visits to the hospital 1.3±0.4 versus 3±2
visits over 3 years, (P<.001;Table 3). Also, insight
preservation correlated with fewer hospitalization
days over the same time period (14.5 days versus
38 days; P<.001, df=9, f=4.5).
Mood and Affect
The group with better insight had more com-
plaints of depression (P<.0009, df=9, f=16.5)
and more patients complained of anxiety symp-
toms (P=.0002, df=§, t=4A) than the diminished
insight group.
Attention
No differences between groups was found.
Delusions
Although both groups had similar percentages
of patients with thought impairment, the better
insight group had fewer patients with moderate
to severe delusions than the poor insight group
(five versus 10 patients; P=.O15, ctf=9, t=3).
Behavior
The behavioral dimension of the two groups
was examined in terms of referral mode, suicidal
behavior, cooperativeness with assessments,
disposition (involuntary versus other admis-
sion mode), and changes in residence upon dis-
charge. The only differences between groups
were noted in the increased frequency in invol-
untary hospitalizations in the poor insight group
(nine versus three patients; P<.0001, d/^13, t=5),
and more patients in the good insight group
were cooperative with assessments (eight of 10
versus eight of 14; P<.002, c#=9, f^4.4).
During the hospitalizations there was no
difference between the groups in numbers
of group therapy that they attended (P=0.18).
However, patients with poor insight received
more PRN medication (antipsychotic and anti-
anxiety agents were most frequently used for
this purpose) for behavioral problems (P=0.001,
TABLE 3 .
Indicators of Impact
N
Employed (n)'
Hospitalization
days'
ED visits'
PRN for agitation*
Insight
group
10
6
14.5
1.3±0.4
3
of Illness
Diminished
insight
14
1
38
3±2
7.4
' A t the initial presentation.
' Over a 3-year period.
* Controlled for the length of hospitalization.
ED=emergency department.
Bota RG, Munro JS, Ricci WF, Bota DA. CNS Spectr. Vol 11,
P
value
^=.005
P<.001
Fk.001
P<.005
No 5. 2006.
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df=13, f=4.3).The presence of insight predicted
better judgment on psychiatric evaluation.
There was no difference between groups in the
number of patients referred by either police or fam-
ily. However, when examining the entire sample's
pattern of presentations, while the patients' family
referred them to the ED in the early stages of the
prodromal phase of illness, the family became
less involved when the patients were diagnosed
initially with schizophrenia and at the subsequent
presentations (P<.0005 and P<.0003). Also, the
presentations at which the police referred patients
increased at the time of schizophrenia diagnosis,
and at the subsequent presentations when com-
pared with the prodromal period (P<.0055 and
P<.0015, respectively).
Retrospective Reliability of Information
Regarding Prodromal Period
Patients and family members described early,
ego-dystonic perceptual disturbances followed by
diminished insight.This led to incipient delusion
systems, usually paired with noticeable behav-
ioral changes, which, in time, led to bizarre behav-
iors and delusions. When we analyzed the data
for all the patients, the following timeline was
identified: 44 months preceding the diagnosis
of schizophrenia initial symptoms were reported
and reported behavioral changes occurred on
average of 19.4 months before the initial schizo-
phrenia diagnosis. The timeline of symptoms
was evaluated for the patients in the two groups
(Figure 2).The patients in the good insight group
FIGURE 3 .
Perception of progression of symptoms
(months from the reported events to
diagnosis of schizophrenia)
• Visits Before Diagnosis
• Behavior Changes • Perception Changes
28.5
All Patients
No Insight
Insight
0 10 20 30 40 50 60
Months before the initial schizophrenia diagnosis
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reported earlier initial symptoms, followed by
initial behavioral changes, and then the first psy-
chiatrist assessment. For the poor insight group,
the initial symptoms were reported closer to the
initial diagnosis of schizophrenia and behavioral
changes were reported 18 months after the initial
psychiatric assessment.
DISCUSSION
In our study, the better insight group had more
complaints of depressive and anxious symptoms
which did not correlate with a higher rate of sui-
cidal behavior.They also had less severe delu-
sions, fewer involuntary hospitalizations, and
a greater tendency to be cooperative with the
assessments than the poor insight group. Given
this correlation between insight and better prog-
nosis, researchers may find motivation to explore
interventions that would preserve or improve
insight in patients with impending schizophrenia.
The most striking difference between the groups
was that the reported debut of incipient experien-
tial symptoms, marking the debut of the prodromal
period, and the debut of behavioral changes, were
skewed toward shorter duration of the reported
symptoms in the poor insight group, even though
on average they had a psychiatrist evaluation ear-
lier in the prodrome than the good insight group.
There are several implications of this finding.
First, clinicians may underestimate the sever-
ity and duration of symptoms in the patients
with poor insight because they must rely on
self-report. Secondly, clinicians identifying pro-
dromal symptoms in patients with poor insight
may be prompted to treat these symptoms more
aggressively. Finally, the selection of patients in
the research studies may be skewed. For exam-
ple, patient populations in the studies regarding
the duration of untreated psychosis, may over-
represent the patients that are aware of need for
treatment by including more patients with better
insight. This could alter the findings in terms of
duration of untreated symptoms and prognostic
value of treatment. This could explain, at least
partially, the contradictory data in the literature
about the correlation between the duration of
untreated psychosis and prognosis.
Sevy and colleagues20 reported that poor aware-
ness into illness correlates with severity of the ill-
ness (established schizophrenia). In our study, it
was difficult to assess if poor insight into the ill-
ness was the cause for the worse prognosis of
the illness or merely an indicator of worse illness.
CNS Spectr 1 1:5 360 May 2006
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Furthermore, we are unaware of other published
data of insight into the illness in the prodrome of
schizophrenia to provide additional information. In
future studies, separate raters could independently
evaluate insight and severity of illness.This would
better address the issue of a causal linkage.
In schizophrenia, suicide is the leading cause
of premature death.41 Although in this study there
were differences between groups in terms of
anxiety and depressive symptoms, no significant
increase in suicidal ideation and suicidal behav-
ior in the good insight group were found. Other
studies42-43 also reported no correlation between
the degree of insight and suicidality in patients
with established schizophrenia. Suicidal behav-
ior may correlate with certain aspects of aware-
ness and not with others (eg, affective or cognitive
domains associated with insight not evaluated
here). Patients with awareness regarding symp-
toms (delusions, poor socialization, blunted affect,
anhedonia) and need for treatment but lacking
awareness into the general concept of having an
illness may have a higher degree of suicidality.41 By
contrast, Kim and colleagues44 found that patients
that scored higher on the items of the Schedule
for Affective Disorders and Schizophrenia, reflect-
ing insight in general, had more suicidal ideation
and Crumlish and colleagues46 suggests that rec-
ognition of mental illness in the first 6 months
after diagnosis predicts suicide in the first 4 years
following the schizophrenia diagnosis. Harkavy-
Friedman and Nelson46 suggests that an increase
in suicidal behavior is associated with symptoms
such as psychosis and depression. In summary,
various insight domains are associated with sui-
cidal behavior and it is difficult to predict suicidal
behavior solely on the basis of insight. In a recent
review,47 it was suggested that working through
the grief associated with facing the developing
illness and attaining usable insight that integrates
affective and cognitive components can reduce
suicidal risk in this patient population.
One limitation of this study is typical of retro-
spective chart reviews, in that there was no con-
trol of gender, racial and other demographic fac-
tor distribution. A second limitation is small sam-
ple size. Also, it was difficult to determine from
the medical records if interventions initiated by
psychiatrists in other facilities were intended for
treatment of prodromal symptoms or comorbid
conditions. Furthermore, the mission of the hospi-
tal public mental health services targets a patient
population with a high rate of uninsured patients
who tend to use services for acute inpatient treat-
ment and outpatient-like services (eg, ED visits for
medication refill). On the other hand, in another
study, Bota and colleagues48 found that 40% of the
patients with an established diagnosis of schizo-
phrenia for 8 years and treated in the same facility
had a history of travel from state to state. Such a
pattern was not observed in this cohort.
Patients experiencing prodromal symptoms
frequently visit a physician (75% and 90% respec-
tively) prior to the onset of psychosis,4950 provid-
ing opportunities for identification of individuals
at high risk of developing schizophrenia5163 and
allowing for insight assessment and insight ori-
ented interventions.
There was considerable variation in the dura-
tion of the prodrome across the studies reviewed.
Huber and Gross54 reported a duration of the pro-
drome at up to 6 years and Cornblatt and col-
leagues56 treated patients with the prodrome for
3 years. In another study,49 the duration was 44
months. This may reflect differences in selec-
tion of patients and definition of the prodrome.
Overall, patients are believed that present for
evaluation during a continuum in the prodromal
period. However, there are phenomenological
differences between different periods of the pro-
drome. In one study,66 by plotting presentation
time in relation to the time of schizophrenia diag-
nosis one sharp peek was observed at 7 months.
The other patients' presentations had a bigger
standard deviation and averaged at 32 months
before the diagnosis of schizophrenia. Having an
early presentation may not predict better insight
into symptoms or illness as most of these evalua-
tions were initiated by the families of the patients.
It is possible that the insight into the illness and
into the relation between need for treatment and
illness predicts better prognosis regardless of
presentation timeframe. However, this hypothesis
needs to be studied. Furthermore, we suggest
that prodromal evaluation of insight can give us
clues regarding prognosis.
CONCLUSION
Previous research has shown that by using var-
ious interventions,32"35 insight can be improved in
patients with schizophrenia. Further research in
this area is warranted to determine if early insight
oriented interventions in the prodromal phase
can improve the prognosis of schizophrenia.The
answer may lie in the interplay between the knowl-
edge of the self and the knowledge of others. CNS
CNS Spectr 1 1:5 361 May 2006
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